Fresh Tracks Therapeutics Statistics
Total Valuation
Fresh Tracks Therapeutics has a market cap or net worth of 4.45 million. The enterprise value is -6.42 million.
| Market Cap | 4.45M |
| Enterprise Value | -6.42M |
Important Dates
The next estimated earnings date is Friday, March 14, 2025.
| Earnings Date | Mar 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Fresh Tracks Therapeutics has 5.97 million shares outstanding. The number of shares has increased by 92.11% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 5.97M |
| Shares Change (YoY) | +92.11% |
| Shares Change (QoQ) | +1.11% |
| Owned by Insiders (%) | 1.60% |
| Owned by Institutions (%) | n/a |
| Float | 4.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.50 |
| PB Ratio | 0.45 |
| P/TBV Ratio | 0.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 1.13 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.98
| Current Ratio | 6.98 |
| Quick Ratio | 6.59 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,272.00 |
Financial Efficiency
Return on equity (ROE) is -66.50% and return on invested capital (ROIC) is -46.29%.
| Return on Equity (ROE) | -66.50% |
| Return on Assets (ROA) | -36.37% |
| Return on Capital (ROIC) | -46.29% |
| Revenue Per Employee | 2.00M |
| Profits Per Employee | -1.42M |
| Employee Count | 4 |
| Asset Turnover | 0.73 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.50% in the last 52 weeks. The beta is 0.47, so Fresh Tracks Therapeutics's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | -7.50% |
| 50-Day Moving Average | 0.73 |
| 200-Day Moving Average | 0.84 |
| Relative Strength Index (RSI) | 60.30 |
| Average Volume (20 Days) | 2,326 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.21 |
Income Statement
In the last 12 months, Fresh Tracks Therapeutics had revenue of 8.01 million and -5.69 million in losses. Loss per share was -1.06.
| Revenue | 8.01M |
| Gross Profit | 4.82M |
| Operating Income | -6.36M |
| Pretax Income | -5.69M |
| Net Income | -5.69M |
| EBITDA | -6.32M |
| EBIT | -6.36M |
| Loss Per Share | -1.06 |
Balance Sheet
| Cash & Cash Equivalents | 10.87M |
| Total Debt | n/a |
| Net Cash | 10.87M |
| Net Cash Per Share | 1.82 |
| Equity (Book Value) | 9.93M |
| Book Value Per Share | 1.66 |
| Working Capital | 9.90M |
Cash Flow
| Operating Cash Flow | -4.34M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 60.25%, with operating and profit margins of -79.44% and -71.12%.
| Gross Margin | 60.25% |
| Operating Margin | -79.44% |
| Pretax Margin | -71.12% |
| Profit Margin | -71.12% |
| EBITDA Margin | -78.93% |
| EBIT Margin | -79.44% |
| FCF Margin | n/a |
Dividends & Yields
Fresh Tracks Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -92.11% |
| Shareholder Yield | -92.11% |
| Earnings Yield | -141.68% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on July 5, 2022. It was a reverse split with a ratio of 0.0222222.
| Last Split Date | Jul 5, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.0222222 |
Scores
Fresh Tracks Therapeutics has an Altman Z-Score of -19.21. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -19.21 |
| Piotroski F-Score | n/a |